[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 21, 1988

Phenoxybenzamine in Benign Prostatic Obstruction

Author Affiliations

Salem, NJ
Lancaster, Pa

Salem, NJ
Lancaster, Pa

JAMA. 1988;260(15):2220. doi:10.1001/jama.1988.03410150068031

To the Editor.—  In a recent assessment of prostatectomy for benign prostatic urinary tract obstruction,1 it was pointed out that despite the improvement of most patients, the surgical mortality and frequency of complications are higher than reported in the literature. This prompts us to report our anecdotal experience with the αadrenergic blocker phenoxybenzamine. We have given this drug to an estimated 80 patients with symptomatic prostatic hyperplasia. Most of these patients have experienced prompt and substantial relief of their symptoms and improved bladder emptying within three or four days. No decrease in effectiveness has developed in patients treated for as long as six years. A dosage of 10 mg daily generally has been adequate and rarely has resulted in significant side effects. Although phenoxybenzamine has been oncogenic in some rodent tests, this effect has not been reported in humans.In an excellent recent review, Caine2 speculates that the